June 5 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients continued to lose ...

Everything you need to know to watch all the Cup Series action in 2026. The Sporting News Cuándo juega, cómo y dónde ver al Inter Miami: Día, hora, canal de TV y streaming online del partido vs. Cruz ...

A Structure Therapeutics obesity pill helped patients lose an average of nearly 40 pounds in a mid-stage clinical trial, keeping the drug competitive in the growing crowd of oral medications pursuing ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Structure Therapeutics said Monday that its ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

As one of the most heavily regulated foods on the market, infant formula is subject to strict nutrition guidelines and undergoes rigorous safety and quality testing. But CR’s tests of infant formula ...

Jan 14 (Reuters) - Structure Therapeutics' (GPCR.O), opens new tab CEO expects oral weight-loss pills to capture as much as half of the GLP-1 market by 2030, driven partly by pent-up demand from ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...

There is more to Formula 1 than its swift speeds. Behind these thrilling races are integral parts and mechanics that come at a staggering price, all for the sake of victory. Normal cars can be ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...